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Genotyping for CYP2D6 has the potential to predict differences in metabolism of nortripty-
line. This information could optimize pharmacotherapy. We determined the costs and
effects of routine genotyping for old aged Dutch depressed inpatients.
Methods
With a decision-tree, we modelled the first 12 weeks of nortriptyline therapy. Direct costs
of genotyping, hospitalization, therapeutic drug monitoring and drugs were included.
Based on genotype, patients could be correctly, sub-, or supratherapeutically dosed.
Improvement from sub- or supratherapeutically dosed patients to correctly dosed patients
was simulated, assuming that genotyping would prevent under- or overdosing of patients.
In the base case, this improvement was assumed to be 35%. A probabilistic sensitivity
analysis (PSA) was performed to determine uncertainty around the incremental cost-
effectiveness ratio (ICER).
Results
In the base case analysis, costs for genotyping were assumed €200 per test with a corre-
sponding ICER at €1 333 000 per QALY. To reach a €50 000 per QALY cut-off, genotyping
costs should be decreased towards €40 per test. At genotyping test costs < €35 per test,
genotyping was dominant. At test costs of €17 per test there was a 95% probability that gen-
otyping was cost-effective at €50 000 per QALY.
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Conclusions
CYP2D6 genotyping was not cost-effective at current genotyping costs at a €50 000 per
QALY threshold, however at test costs below €40, genotyping could be costs-effective.
Introduction
Major depressive disorder (MDD) is a disease with a significant burden of disease in the aging
European population [1]. Antidepressants can be used in the treatment of MDD. There are dif-
ferent classes of antidepressants, with the tricyclic antidepressants (TCAs) representing a treat-
ment option typically initiated after unsuccessful treatment with a selective serotonin reuptake
inhibitor (SSRI) [2]. Based on the most favorable side-effect profile, nortriptyline is the TCA of
first choice among older patients as advised by different guidelines [3,4]. In contrast to most
SSRIs, TCAs display a clinically relevant concentration-effect relationship and therefore thera-
peutic drug monitoring (TDM) is strongly recommended [5].
Nortriptyline is metabolized by the polymorphic cytochrome P450 2D6 (CYP2D6) enzyme
[6]. Generally, its polymorphisms are classified into four different phenotypes: poor metabolizer
(PM), intermediate metabolizer (IM), extensive metabolizer (EM) or ultra-rapid metabolizer
(UM) [7]. Notably, EMs represent the most prevalent group in Caucasian populations. Com-
pared to the EMs, PMs and IMs have a decreased activity of the CYP2D6 enzyme, whereas UMs
have an increased activity of this enzyme. As a result of this variance in enzymatic activity,
patients display large variations in plasma concentrations despite similar drug dosages [8–10].
In addition to TDM, to further improve pharmacotherapy with nortriptyline, routine test-
ing for CYP2D6 has been proposed to facilitate dose adaptations in an early stage of pharmaco-
therapy [11]. Especially in aged patients, genotyping might be beneficial, because patients
above 60 years are more frequently exposed to higher plasma concentrations of nortriptyline
[12]. Although the literature is not completely unambiguous, these higher plasma concentra-
tions might relate to more and/or more severe adverse drug reactions (ADRs) [13,14]. Besides
a reduction in ADRs, better efficacy of nortriptyline can be expected in patients whose plasma
concentrations are within therapeutic range, since sub- or supratherapeutic plasma concentra-
tions of nortriptyline can reduce the efficacy of the drug [5,15,16]. Potentially related to reduc-
tions in ADRs and an increased efficacy, suggestions have been made that CYP2D6 genotyping
can reduce psychiatric hospitalization costs [11,17–20]. For schizophrenic patients who used
CYP2D6 dependent antipsychotic agents, this was recently demonstrated in Denmark [21].
To facilitate dose finding of nortriptyline with the use of genetic information, specific guide-
lines for dose adaptations of nortriptyline have recently become available [22]. Indeed, in some
secondary psychiatric care facilities in the Netherlands, genotyping is already implemented as care
as usual [23]. However, no information concerning the cost-effectiveness of routine genotyping at
the start of nortriptyline treatment among depressed hospitalized patients is available. We con-
structed a pharmacoeconomic model, to assess cost-effectiveness of routine genotyping. As safe
and fast dose finding is considered particularly important among severely depressed aged patients,
we designed the model to simulate a Dutch hospitalized population of 60 years and older.
Methods
Design
To evaluate the cost-effectiveness of CYP2D6 genotyping, a decision-tree was built in Micro-
soft Excel version 2010. Within this model, two virtual cohorts of 1000 depressive patients
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with an age of 60 years or older and treated with nortriptyline were simulated. In one cohort
patients were genotyped whereas in the other patients received care as usual. Subsequently,
costs and health outcomes of both cohorts were compared.
According to the Dutch guideline on depression (addendum elderly), patients should be
titrated towards a dose of 75 mg per day which takes approximately 12 days [4]. At this dose,
plasma concentrations should be evaluated. Therefore, we assumed that in the model, plasma
concentrations of all patients were evaluated after 12 days. As a result of this evaluation,
patients were labeled to have either received a correct dosage, suboptimal dosage, suprathera-
peutic dosage or had discontinued therapy. Patients who were not optimally dosed received a
dose adaptation and a second evaluation of plasma concentration. Patients who were still
incorrectly dosed after this second evaluation received one more dose adaptation and control
of plasma concentration and were assumed to be correctly dosed afterwards. Patients who dis-
continued nortriptyline pharmacotherapy entered the next step of treatment (i.e. tranylcypro-
mine 40 mg) which was initiated after a wash out period of 14 days [2]. The structure of the
decision-tree is shown in Fig 1. For both the “care as usual” and “genotyping” cohorts the
same structure was used, although the input variables were different.
All patients in the simulated treatment cohorts were hospitalized in a psychiatric hospital
for an episode of severe depression which was followed by discharge. Patients were structured
Fig 1. Model structure for the treatment of major depressive disorder with nortriptyline during the
first 12 weeks. Patients who receive a dosage which led to therapeutic plasma concentrations (i.e. “correct”)
did not receive a next dose evaluation. Patients who quit nortriptyline pharmacotherapy entered a wash out
period with a disutility of 0.20 for 14 days. After this period, pharmacotherapy with 6 tranylcypromine was
initiated for the remaining time in the model. PM = poor metabolizer, IM = intermediate metabolizer,
EM = extensive metabolizer, UM = ultrarapid metabolizer.
doi:10.1371/journal.pone.0169065.g001
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by their genotypes. For simplification of the model, different genotypes led to specific assump-
tions. First, PMs and IMs could only receive a dose that was either correct or too high. In addi-
tion, after dose adjustment, dosing could not become incorrect in an opposite way. For
example, when an EM was dosed too high, the dose could not become too low after adjust-
ment. An UM could only receive a dose that was either correct or too low.
As mentioned before, most patients had an EM genotype, however distribution of geno-
types is dependent on the ethnicity of a population. For this study, we used frequencies that
are reported for European Caucasian populations (Table 1) [24,25].
Time horizon
It was assumed that CYP2D6 genotype information would only optimize dose finding of nortrip-
tyline during the titration phase. Therefore, effects were limited to the timespan of the titration
phase. According to expert opinion, this phase is usually completed within three evaluations. As
such, we chose a time horizon of maximally three evaluations. To assess the time it would take for
three evaluations to occur, we used guideline recommendations and retrospective (2009–2014)









Effect of genotyping (i.e. improvement of
incorrectly dosed to correctly dosed) (%)
35 31–38 β (253, 470) [28] No
Incorrectly dosed until first evaluation (%)
Poor metabolizer too high 76 73–78 β (735, 239) [28] No
Intermediate metabolizer too high 56 53–59 β (572, 443)
Extensive metabolizer too high 12 n.a. n.a.
Extensive metabolizer too low 25 n.a. n.a.
Ultra-rapid metabolizer too low 57 54–60 β (593, 455)
Incorrectly dosed until second evaluation (%)
All genotypes 43 34–53 β (40, 53) S1 Fig Yes
Additional days after start at which an evaluation took place
Dose evaluation 1 12 5–19 γ (11, 1.06) [4] Yes
Dose evaluation 2 31 Dependents on evaluation 1 Dependent on
evaluation 1
S1 Fig Yes
Dose evaluation 3 38 Fixed Fixed S1 Fig Yes
Genotype (% of population)
Poor metabolizer (2 dysfunctional alleles) 8 6–10 Uniform [24] No
Intermediate metabolizer (1 dysfunctional allele) 11 9–13 Uniform
Extensive metabolizer 79 Dependents on other genotypes n.a.
Ultra-rapid metabolizer(duplication of the gene) 2 1–2 Uniform
Hospitalization
Average duration inpatient care (days) 28.6 +/- 25% γ (61, 0.47) [19,38] Yes
Shorter hospital stay when correctly dosed (%) 13 0–26 β (40, 53) [19] No
Patients who discontinue therapy
After first dose evaluation (%) 22 12–33 β (11, 39) [55] No
After second dose evaluation (%) 8.5 2–17 β (3, 37)
Disutility’s
If dosed to high 0.04 0.01–0.12 PERT (0, 0.04, 0.13) [36] No
If dosed to low 0.20 0.12–0.28 β (19, 76) [35]
If discontinue nortriptyline therapy 0.20 0.12–0.28 β (19, 76) assumed
doi:10.1371/journal.pone.0169065.t001
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anonymous TDM data from the Clinical Pharmacy of the Diaconessen Hospital Meppel/Hoogev-
een, the Netherlands (unpublished results; see S1 Fig). First, based on the advices in guidelines, all
patients received the first evaluation 12 days after start of therapy [4]. Second, based on the TDM
data, a second or third evaluation took place after 31 and 38 days. For a total of three evaluations,
this resulted in a 12 weeks’ time horizon of the model. In the model it was assumed that after this
period, patients were either correctly dosed or had discontinued nortriptyline pharmacotherapy.
Effects of genotyping
For economic evaluations of pharmacogenomics the analytical and clinical validity of the
genetic test has to be defined [26]. The analytical validity (i.e. ability of the test to differentiate
between carriers of different alleles) depends on the method which is used, but is in general
known to be very high: >99% for CYP-enzymes [27]. In the model it was therefore assume
that the analytical validity was 100%. The clinical validity of CYP2D6 testing (i.e. the ability of
the test to differentiate between clinical characteristics, like a PM or UM phenotype) depends
on the number and type of variant alleles which are analyzed. In the model, genetic variation
in the CYP2D62, 3, 4, 5, alleles, and duplications of the gene were used for the clinical
effects. These effects were based on the prediction of the PM and UM phenotype among a
European Caucasian population. In a pharmacokinetic model it has been reported that when
CYP2D6 phenotype predictions are based on genetic variations in these alleles 78.5% of PMs
would have supratherapeutic nortriptyline plasma concentrations at a normal daily dose [28].
In the pharmacokinetic model dosing of nortriptyline was adapted based on these CYP2D6
alleles As a result, a 51.1% instead of 78.5% of the patients had supratherapeutic plasma con-
centrations in the PM group. This corresponded to a reduction of ~35% (1- (51.1/78.5) = 0.35)
of inadequately dosed patients [28]. This reduction was used in the base case of our model for
the PM group in the genotyping cohort. For the UM group, an improvement from 60.2% to
39.3% in suboptimal dosed patients was reported which almost equals the effect found in the
PM group (i.e. a 35% reduction in inadequately dosed patients). This effect was also included
in the model. In the base case no effect for IMs or EMs were assumed. In a scenario analysis
we did include effects for IMs (see sensitivity analysis).
Depending on their genotype, PMs and UMs in the ‘genotyping’ cohort received a different
start dosage compared to patients in the ‘care as usual’ cohort. Dose adaptations were based on
the advices given in the Dutch guidelines: 40% of standard dose for PMs and 160% of standard
dose for UMs [29]. A detailed dosing schedule can be found in S1 Table.
Outcome measures
Better efficacy as well as a reduction of ADRs can be expected in patients who have nortripty-
line plasma concentrations within the therapeutic range as compared to outside [5]. Both affect
quality of life. For ADRs, reduced utilities (ranging from: -0.12 to -0.01) among patients who
experience ADRs of antidepressants have been reported [30]. For efficacy, a difference in util-
ity ranging from 0.22 to 0.45 between untreated and treated depression has been described
[30–34]. In addition, a difference in utilities between responders and non-responders to anti-
depressant of 0.20 has been reported [35]. In the model we included a disutility of 0.04 for
experiencing an ADR when dosed supra-therapeutically [36]. The reported difference of 0.20
between non-responders and responders was used as a disutility for subtherapeutic dosed
patients, assuming that patients who were dosed too low, would not respond optimally to nor-
triptyline pharmacotherapy. Among patients who discontinued nortriptyline pharmacother-
apy, a similar disutility of 0.20 was included for the wash out period of 14 days, before the next
treatment step with tranylcypromin was initiated. In the model, these disutility’s were linked
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to the proportions of patients with sub, or supratherapeutic dosages, or to a wash out period
for each day patients were in a certain ‘health state’.
For the first evaluation we assumed correctly dosed patients were patients with a nortriptyline
plasma concentration within the therapeutic range. Proportions of therapeutic, sub-, and sup-
ratherapeutic plasma concentrations were extracted from literature [28]. After the first weeks of
treatment, the effects in terms of antidepressant response, start to improve patient’s utility [37]. At
this stage, in addition to plasma concentration, drug dosing is adapted based on clinical efficacy
and ADRs. Therefore, in the model, the proportion of patients who were incorrectly dosed at the
second evaluation was not based on the plasma concentration, but on the proportion of patients
who had a third TDM request in the clinical pharmacy. As such, it was assumed that patients who
were controlled by TDM for a third time were not correctly dosed before (S1 Fig). Notably, the
TDM data had no information about differences between genotypes. Therefore, conservatively,
we assumed similar proportions of incorrectly dosed patients among all genotypes.
In addition to an improved quality of life, a reduction in hospitalization days was included in
the model. Hospitalization of US patients with MDD and a decreased CYP2D6metabolic capac-
ity was found to be 13% longer than the average (7.8 instead of 6.9 days) [19]. Among the Dutch
population, average hospitalization duration for MDD (from 2007 to 2011) of patients aged 65
or older was 28.6 days [38]. To translate US-results into a Dutch setting, we assumed that based
on genotype guided dosing, a proportionally similar reduction of 3.7 hospitalization days from
the average (0.1328.6 = 3.7) was achieved among eligible patients, by shifting them from sub-
optimal to therapeutically dosed. As a result, patients who were correctly dosed after the first
evaluation were discharged from hospitalization after 24.9 days (28.6–3.7 = 24.9). The remain-
ing patients (i.e. suboptimal dosed patients) were assumed to be hospitalized for 31.6 days to
realize the weighted average of 28.6 days as registered. Main model inputs are shown in Table 1.
Costs
Our evaluation was performed from a health-care insurance payers perspective and only direct
medical costs were included in the model (Table 2). This perspective was chosen, due to a lack
of data concerning effects of genotyping on indirect costs and on the relatively modest produc-
tivity loss to be expected in a population of 60 years and older. Costs and utilities were not dis-
counted, since our model had a time horizon of 12 weeks. Costs were expressed in 2014 price
levels. Drug costs were collected from the website of the Dutch National Health Care Institute
[39] and costs for genotyping and TDM were obtained from the Dutch Healthcare Authority
[40]. Hospitalization costs and costs for consultations with a psychiatrist were obtained from
guideline prices listings and converted to costs in 2014 using the appropriate deflators [41,42].
Table 2. Drug costs included in the model.
Type of costs Costs in 2014
Genotyping (5 DNA amplifications) € 188.20
TDM (per measurement) € 23.11
Hospitalization (per day) € 255.62
Ambulant contact with psychiatrist € 190.62
Nortriptyline




40 mg € 0.96
doi:10.1371/journal.pone.0169065.t002
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Drug and TDM costs were included in hospitalization costs and calculated separately after
patients were dismissed from hospital stay. Based on an average hospital stay of 28.6 days all
patients were assumed to have a first dose evaluation during hospitalization which entailed no
extra costs [38]. For a second or third evaluation additional costs for monitoring were counted.
These costs included costs for TDM as well as¼ of a psychiatric consult for interpretation of
the nortriptyline plasma concentration and, if applicable, dose adaptations. Costs for genotyp-
ing of CYP2D6were based on costs for qualitative DNA amplification at €38 per amplification
[22]. Assuming genotyping would involve testing for five amplifications, costs would be €190
per CYP2D6 test. Note that test costs can be different between labs, due to different methods
used for genotyping (i.e. TaqMan analysis, Roche AmpliChip CYP450, whole DNA sequenc-
ing). Furthermore, we assumed genotype information would be available before or at the
moment of start of nortriptyline treatment.
Cost-effectiveness
The incremental cost-effectiveness ratio (ICER) was calculated by comparing costs and quality
adjusted life years (QALYs) between the two cohorts. In addition break even test costs were
calculated.
Deterministic, probabilistic and scenario sensitivity analysis
Input variables for the deterministic sensitivity analysis are shown in Table 1. The outcomes of
the deterministic sensitivity analysis was reflected in Tornado diagrams.
Threshold analysis was performed on all variables to calculate break even test costs and
maximal test costs to reach the €50 000 per QALY cut off [43]. For further assessment of the
uncertainty, a probabilistic sensitivity analysis (PSA) was performed. The distributions and
parameters of the variables are shown in Table 1. In addition, the probability of cost-effective-
ness at €50 000 per QALY was calculated for various genotyping test costs [43].
Two scenario analysis were performed. First, a scenario in which the proportions of incor-
rectly dosed patients at the second evaluation did differ per genotype was included. For this
differentiation, the same estimates as for the first evaluation were used (i.e. % incorrect evalua-
tion 1 = % incorrect evaluation 2). In the second scenario analysis dose adaptations for IMs
(60% of standard dose) were included [29]. No data was reported about supratherapeutically
dosed IMs or clinical effects of genotyping in the pharmacokinetic model which was used for
the PM and UM genotypes. Therefore, we took the average of the EM and PM group and as
such 56% of the IMs was supratherapeutically dosed. Clinical effects of IM phenotype predic-
tions is unknown, but we assumed an similar effect of 35% improvement among incorrectly
dosed patients. With respect to clinical validity, It has been reported that 38% of CYP2D6 IMs
are false positive [44]. This means, these patients would be dosed too low when dose adapta-
tions would be made based on genotype. Therefore, in this scenario analysis another branch
was included in the decision tree for IM patients who were subtherapeutic dosed. As a result,
38% of the IM patients who were incorrectly dosed in the genotyping cohort, were dosed sub-
therapeutic instead of supratherapeutic. ICERs, QALY loss, break even test costs and test costs
to reach the €50 000 per QALY were calculated for both scenarios.
Results
Base case
In the base case scenario an ICER of €1 333 000 per QALY was found. If test costs were €40,
an ICER of €50 000 per QALY was found and when test costs were €35 per test, test costs
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equaled costs savings (i.e. break even). At lower costs, genotyping would become the dominant
strategy. A summary of the model outcomes is shown in Table 3. The difference in QALY loss
were small. Genotyping resulted in a QALY gain of 0.12. The majority of costs concerned hos-
pitalization costs in the first weeks of treatment. In the genotyping cohort, costs for inpatient
care and follow-up were lower. According to the model, genotyping could save €32 294 of
inpatient care costs, €2 195 for TDM costs, and €244 of drug costs. However, due to genotyp-
ing costs, total costs in the genotyping cohort were higher.
Deterministic, probabilistic and scenario sensitivity analysis
The results of the deterministic sensitivity analyses are shown in Fig 2. Reduction in the dura-
tion of hospitalization among correctly dosed patients emerged as the most important parame-
ter. When no reduction of inpatient care was assumed, test costs should be €2 to reach the €50
000 per QALY cut off, or €8 to break even. The proportion of patients discontinuing nortripty-
line pharmacotherapy in the first weeks of therapy markedly influenced the ICER. When more
patients continued nortriptyline pharmacotherapy, genotyping became more effective. With
respect to quality of life, the utilities gained by preventing too high dosing had more influence
on the ICER compared to the utilities gained by preventing patients who were dosed to low,
even though there was more utility loss counted per case for the latter (0.20 vs. 0.04).
The PSA revealed that in the base case scenario (i.e. at current genotyping costs) a probabil-
ity applied of<1% for genotyping to be cost-effective (€50 000 per QALY). If genotyping costs
were €17 a probability of>95% genotyping to be cost-effective applied (€50 000 per QALY).
Cost-effectiveness acceptability curves of the maximal CYP2D6 test costs to obtain an ICER of
€50 000 per QALY and breakeven test costs are shown in Fig 3.





Difference ICER (€) Max. test costs for €50 000/
QALY (€)
Base case
Patients with 24.9 days of inpatient care (correctly
dosed)(n)*
483 447 36
Days of inpatient care (mean) 28.60 28.47 - 0.13
Patients who stopped therapy (n) 248 247 -1
Costs of care (€) 7 374 826 7 340 091 - 34 734
Costs CYP2D6 genotyping (€) 0 188 200 188 200
Total costs (€) 7 374 826 7 528 292 153 466




Scenario analysis; including genotype based differences for incorrectly dosed patients at
evaluation 2
Total costs (€) 7 375 299 7 528 218 152 918
QALY loss 4.50 4.34 0.15
999 622 43
Scenario analysis; including dose adaptations for IMs
Total costs (€) 7 374 826 7 497 172 122 346




* Suboptimal dosed patients were hospitalized for 31.5 days.
doi:10.1371/journal.pone.0169065.t003
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The first scenario analysis indicated that when proportions of incorrectly dosed patients
at the second evaluation equaled those of the first evaluation, this would increase the test costs
to reach the €50 000 per QALY cut-off with €3 (i.e. €43 vs. €40 per test in the base case). This
scenario analysis had no influence on break even test costs. In the scenario analysis which
included dose adaptations for IM, test costs to reach the €50 000 per QALY cut-off or break
even were identified at €68 or €66, respectively, due to more costs savings by reduced inpatient
care of correctly dosed IMs. Although the costs in the genotyping cohort were lower in this
scenario, a QALY loss among false positive IMs was introduced by genotyping. This was due
to a larger utility loss when dosed sub- instead of supratherapeutic. As a result, incremental
utility gain in the genotyping cohorts was reduced with 0.07 towards a remaining QALY gain
of 0.05 in the genotyping cohort. Consequently, a higher ICER of €2 400 000 was found. If the
proportion of falls positive IMs was decreased towards 26% (instead of 38%) an ICER, similar
to the base case scenario was found.
Discussion
Our cost-effectiveness study assessed possible economic implications of genotyping for CYP2D6
among older hospitalized and depressed patients who start nortriptyline therapy. The results
were mainly dependent on genotyping costs. At a price of €190 per test, we found genotyping
Fig 2. Results of deterministic sensitivity analyses for genotyping test costs to reach the €50 000/
QALY cut-off (A) or to break even with costs savings (B).
doi:10.1371/journal.pone.0169065.g002
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for CYP2D6 unlikely to be cost-effective. In the PSA, a probability of<1% was found at the €50
000 per QALY threshold. However, when genotyping costs were<€35 per test, genotyping was
found to be dominant. Within countries costs for CYP2D6 genotyping can be different between
labs. For example, in the UK costs of £30 (€39) and £500 (€645) are reported whereas in US
costs of $439 (€363) are found, respectively [45]. In these labs, the variant alleles studied in our
model are usually included and amended with analysis of other alleles. Based on our model, pur-
chasing these tests for routine genotyping of patients who start nortriptyline pharmacotherapy
will unlikely be cost-effective. Furthermore, broader genotyping packages exist, for example
including other genes like CYP2C19 and CYP2C9. For such packages, even higher test costs of
$914 (€1106) are reported [46]. Nevertheless, many patients aged> 60 years will receive poly-
pharmacotherapy. For these patients, information about different genes might be beneficial and
cost-effective due to multiple drug-gene interactions. Pharmacogenetic tests which asses these
multi-drug and gene interaction can be key towards cost-effectiveness of genotyping, although
the generalizability of these studies will be challenging [47,48]. Besides genotyping costs, the
main parameters which influenced the ICER were the improvement in the duration of hospitali-
zation among correctly dosed patients, mean duration of hospitalization, and the proportion of
patients who discontinued nortriptyline pharmacotherapy. In scenario analysis, inclusion of
dose adaptations for IMs was found to increase the costs savings, but decrease QALY gain, due
to false positive IM genotypes which resulted in more subtherapeutic dosed patients. Based on
this model, it was found that inclusion of dose adaptations for IMs does decrease the cost-effec-
tiveness of genotyping. To obtain a similar ICER as in the base scenario a better correlation than
currently reported, between genotype and phenotype of IMs, is needed.
Our analysis has some limitations. Firstly, the model was based on some assumptions of
which the most important one was the genotyping-facilitated effect in 35% of patients transfer-
ring from sub- or supra-therapeutically dosed to therapeutically dosed. Except for the
Fig 3. Probability on cost-effectiveness at €50 000 per QALY (solid line) or probability of test costs to
break even with cost-savings (broken line) shown at different CYP2D6 genotyping test costs.
doi:10.1371/journal.pone.0169065.g003
Cost-Effectiveness of CYP2D6 Genotyping in Older, Depressed Patients Starting Nortriptyline Therapy
PLOS ONE | DOI:10.1371/journal.pone.0169065 December 29, 2016 10 / 16
pharmacokinetic modeling study, a description of such estimates was not found [28]. It is
important to obtain better estimates about the effects of genotyping to increase the reliability
of the established cost-effectiveness of genotyping. In addition, we only included genotype spe-
cific variation in the estimate of the proportion of incorrectly dosed patients at the first evalua-
tion and not at the second evaluation, due to a lack of data. In scenario analyses, inclusion of
such a differentiation was found to have almost no influence on the breakeven test costs and
only a minor increase in the maximum test costs for the €50 000 per QALY cut-off. Secondly,
the relation between ADRs and high plasma concentrations of nortriptyline is maybe not as
straightforward as in our model [49]. Nevertheless, among antidepressants, tricyclic antide-
pressants like nortriptyline have a well-accepted concentration-effect relationship and ADRs
can give a lower quality of life [5,30]. Moreover, the upper limit of the therapeutic range is not
solely there due to the occurrence of ADRs. Patients with a supratherapeutic dose often display
non-response, irrespective of ADRs, and therefore it is important to maintain the upper limit of
the therapeutic range [9]. Therefore, a disutility of 0.04 for patients with supratherapeutic plasma
concentration as included in our model, was considered reasonable. Lastly, we assumed patients
who were dosed to low would not be dosed too high after dosed adjustments, and vice versa for
patients who were dosed to high. This is an oversimplification of the reality, however, consider-
ing the relative wide range of the therapeutic window of nortriptyline is it a fair assumption for
most of the patients. In addition, when not applying this simplification, the effects of including
other branches in the model, would have had little effect on our estimates due to the small num-
ber (n<50) of patients with deviating genotypes who were still incorrectly dosed at the second
evaluation.
Similar approaches as sketched here for depressed patients can be found in other disease
areas. In a trial based analysis of genotyping for thiopurine methyltransferase (TMPT) in com-
bination with azathioprine treatment it was found that clinicians continued to give a low dos-
ing although the genotype information suggested otherwise [50]. Therefore, we did not
assume an effect of genotyping among the EMs, however if such an effect can be demonstrated,
this will markedly influence the ICER in favor of the genotyping strategy.
There are over 100 alleles reported which influence the CYP2D6 phenotype. The prevalence
of the different alleles depends on the ethnicity of a population [24]. Consequently, the relation
between genotypes and phenotypes can be different between populations when tested for the
same set of alleles and is likely to increase when a test includes more alleles [51]. According to
their methods, Jornil et al. only included variation explained by four alleles and duplications of
the gene in their estimates [8]. In our model, we included testing and therefore costs for these
alleles. However, testing for additional alleles is likely to improve the linkage between geno-
types and phenotypes (i.e. clinical sensitivity and specificity of the test). Therefore the 35%
reduction of incorrectly dosed patients which we included as the effect of genotyping might be
a slight underestimation. Nevertheless, testing for more alleles will likely, but not necessarily,
increase costs as and will need additional economic evaluation. Beside clear differences like
costs, differences between countries and labs in methods for analyses of the CYP2D6 gene and
the resulting analytical and clinical accuracy should be considered when extrapolating our
results to other regions or countries.
Two studies assessing clinical utility of genotyping for CYP2C9 in combination with war-
farin therapy found contradicting results. Consequently, the authors emphasized the impor-
tance of the moment in time of genotyping and effect measurement [52,53]. For warfarin,
methods to correct for differences in metabolism between patients like TDM, gender, and
age based algorithms are well developed. Therefore, effects of genotyping depend on exist-
ing monitoring methods and the study design. Moreover, effects would predominantly be
observed in the first weeks of therapy. With our model, we tried to capture such little effects
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in the first weeks of nortriptyline pharmacotherapy which might be challenging to find in
observational studies. We assumed an optimal situation in which genotype information was
available before start of treatment. This is an essential assumption, because if a lab is not
able to provide the information at this moment in time, effects of genotyping will be diluted
and the ICER will increase. On the other hand, if preemptive genotyping is applied, geno-
type information may already be available when a patient is diagnosed with MDD. Further-
more preemptive genotyping can be organized with better efficiency when compared to ad-
hoc genotyping, since multiple samples can be grouped together for laboratory analysis.
This could include more genes than the CYP2D6 gene only and in addition lead to lower
genotyping costs, leading to a lower ICER. The provided information could be used in dif-
ferent situations during a patients’ lifetime and should therefore not only be allocated to
MDD specifically.
Matchar et al., analyzed the possible effect, but not cost-effectiveness of genotyping for
CYP2D6when a selective serotonin reuptake inhibitors (SSRIs) was indicated [54]. They used
fluoxetine as a model SSRI to be influenced by CYP2D6 polymorphisms. Similar to our model,
the authors had to make substantial assumptions. In addition, they used an expert opinion to
predict the clinical effects of genotyping in relation to treatment response. As a consequence,
one of their main recommendations was to conduct a prospective study to assess the real clini-
cal effects of genotyping. The same holds true for our model, however our assumptions were
based on a thorough pharmacokinetic study [28]. In addition we performed an extensive sensi-
tivity analysis to give insights into the uncertainty. Therefore we consider our estimates valu-
able for decision makers.
Currently some of the authors are performing a prospective trial (the CYSCE trial) to evalu-
ate outcomes of CYP2D6 genotyping among patients who will be initiated on nortriptyline
therapy. Patient inclusion already started when we conducted this cost-effectiveness analysis,
so we were unable to use these outcomes for the trial design. However the trial gave insight in
current processes in psychiatry in The Netherlands, which was necessary to build a realistic
cost-effectiveness model.
Conclusions
A cost-effectiveness analysis on effects of genotyping for the CYP2D6 enzyme in older Dutch
inpatients treated with nortriptyline was performed. The effects of genotyping were estimated
with a decision tree. At current costs, genotyping was not cost-effective. Our finding suggests
genotyping would be cost-effective (i.e. €50 000 per QALY) when genotyping costs were
decreased towards €40 per test. When genotyping costs were decreased towards €35 per test,
genotyping was found to be the dominant treatment option.
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